Prevalence of human papilloma virus infection in pregnant Turkish women compared with non-pregnant women

Purpose of Investigation: We aimed to find a prevalence of human papilloma virus (HPV) in order to define the 100 genotypes and subset of 14 oncogenic genotypes in pregnant Turkish women and to compare these with nonpregnant women. Methods: Cervical thinprep specimens were obtained from 164 women in the first trimester pregnancy and 153 non pregnant women. Results: 29.2% of pregnant versus 19.6% of nonpregnant Turkish women had at least one of the 100 types of HPV infection - a statistically significant dif-ference. The rate of 14 high-risk HPV genotype infections was significantly higher in pregnant (14.6) compared to nonpregnant Turkish women (9.6%). onclusions: Pregnant Turkish women are at higher risk for all HPV infections including high-risk cervical cancer genotypes.

Human papillomavirus; Cervical cancer; Turkish women; Prevalence; Genotyping.

[1] Pisani P., Bray F., Parkin D.M.: “Estimates of the world-wide prevalence of cancer for 25 sites in the adult population”. Int. J. Cancer, 2002, 97, 72.

[2] Pisani P., Parkin D.M., Bray F., Ferlay J.: “Estimates of the world-wide mortality from 25 cancers in 1990”. Int. J. Cancer, 1999, 83, 18.

[3] Iihara K., Shiozaki H., Tahara H., Kobayashi K., Inoue M., Tamura S. et al.: “Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma: Implication for the autocrine proliferation”. Cancer, 1993, 71, 2902.

[4] Parkin D.M., Bray F., Ferlay J., Pisani P.: “Global cancer statistics, 2002”. CA Cancer J. Clin., 2005, 55, 74.

[5] Castle P.E., Hillier S.L., Rabe L.K., Hildesheim A., Herrero R., Bratti M.C. et al.: “An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV)”. Cancer Epidemiol. Biomark. Prev., 2001, 10, 1021.

[6] Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S. et al.: “Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analy-sis”. Lancet, 2005, 366, 991.

[7] Richardson H., Franco E., Pintos J., Bergeron J., Arella M., Telier P.: “Determinants of low-risk and high-risk cervical human papil-lomavirus infections in Montreal University students”. Sex. Transm. Dis., 2000, 27, 79.

[8] Franco E. (ed.): “Epidemiology of anogenital warts and cancer. Obstetrics and Gynecology Clinics of North America: Human Papillomavirus I”. 1996, Philadelphia, W. B. Saunders.

[9] ZurHausen H., deVilliers E.M. (eds): “Human papillomavirus”. Annu. Rev. Microbiol., 1994, 48, 427.

[10] Bosch F.X.: “The rolling dossier of cervical cancer prevention”. HPV Today (August 9, 2006), 2.

[11] Meijer C.J., Snijders P.J., Castle P.E.: “Clinical utility of HPV genotyping”. Gynecol. Oncol., 2006, 103, 12.

[12] Apgar B.S., Zoschnick L., Wright T.C. Jr.: “The 2001 Bethesda System terminology”. Am. Fam. Phys., 2003, 68, 1992.

[13] De-Roda H.A., Walboomers J.M., Vanden B.A., Meijer C.J., Snijders P.J.: “The use of general primers GP5 and GP6 elongated at their 3’ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR”. J. Gen. Virol., 1995, 76, 1057.

[14] Sotlar K., Diemer D., Dethleffs A., Hack Y., Stubner A., Vollmern N. et al.: “Detection and typing of human papillomavirus by e6 nested multiplex PCR”. J. Clin. Microbiol., 2004 , 42, 3176.

[15] Bell M., Schmidt G.D., Patrick S., Ryschon T., Linz L., Chauhan C. S.: “There is a high prevalence of human papillomavirus infection in American Indian women of the Northern Plains”. Gynecol. Oncol., 2007, 107, 236.

[16] Li Y., Wang Y., Jia C., Ma Y., Lan Y., Wang S.: “Detection of human papilloma virus genotypes with liquid bead microarray in cervical lesions of Northen Chinese patients”. Cancer Genetic and Cytogenetics, 2008, 182, 12.

[17] Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S. et al.: “Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis”. Lancet, 2005, 366, 991.

[18] Stockman P. C., Segard C., Bennamar S., Gondry J., Boulanger J. C., Sevestre H. et al.: “Prevalence of HPV genotypes determined by PCR and DNA sequencing in cervical specimens from French women with or without abnormalities”. J. Clin. Virol., 2008, 42, 353.

[19] Hrushesky W.J., Sothern R.B., Rietveld W.J., Du Quiton J., Boon M. E.: “Season, sun, sex, and cervical cancer”. Cancer Epidemiol. Biomark. Prev., 2005, 14, 1940.

[20] Hrushesky W.J., Sothern R.B., Rietveld W.J., Du-Quiton J., Boon M. E.: “Sun exposure, sexual behavior and uterine cervical human papilloma virus”. Int. J. Biometeorol., 2006, 50, 167.

[21] Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A, Giuliano A.R. et al.: “Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial”. Lancet Oncol., 2005, 6, 271.

[22] Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M. et al.: “Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial”. Lancet, 2006, 367, 1247.

[23] Koutsky L.A., Harper D.M.: “Chapter 13: current findings from prophylactic HPV vaccine trials”. Vaccine, 2006, 24 (suppl. 3), S121. Koutsky L.A. and Harper D.M.: “Chapter 13: current findings from prophylactic HPV vaccine trials”. Vaccine, 2006, 24 (suppl. 3), S121.